Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19⁺B-cell repopulation

Mult Scler Relat Disord. 2021 Nov:56:103287. doi: 10.1016/j.msard.2021.103287. Epub 2021 Sep 27.

Authors

Nitin Kumar Sahi¹, Syed Muhammad Ali Abidi², Omar Salim², Roby Abraham², Seema Kalra², Adnan Al-Araji²

Affiliations

¹ Royal Stoke MS Centre, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent ST4 6QG, United Kingdom. Electronic address: [email protected].
² Royal Stoke MS Centre, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent ST4 6QG, United Kingdom.

No abstract available

Keywords: CD19; Extended dosing; Multiple sclerosis; Ocrelizumab.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19*
Humans
Pandemics
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
ocrelizumab